The Uromigos
En podkast av The Uromigos
401 Episoder
-
Episode 83: Is cabozantinib the new standard of care in papillary renal cancer?
Publisert: 13.2.2021 -
Episode 81: Noah Hahn discusses front line cisplatin-ineligible PD-L1 data from 361 and 130
Publisert: 13.2.2021 -
Episode 80: Results for Darolutamide in non-metastatic CRPC - the Aramis trial
Publisert: 13.2.2021 -
Episode 79: Adjuvant nivolumab in operable urothelial cancer
Publisert: 13.2.2021 -
Episode 78: Enfortumab Vedotin Special: EV301 randomised trial and EV201 in urothelial cancer
Publisert: 12.2.2021 -
Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC
Publisert: 6.2.2021 -
Episode 76: Tom Hutson discusses lenvatinib and everolimus
Publisert: 22.1.2021 -
Episode 75: The Uromigos meet APCCC - bone health and bone disease in prostate cancer with Bertrand Tombal
Publisert: 14.1.2021 -
Episode 74: The Uromigos meet APCCC Round 2: First line treatment - low vs high volume; chemo vs abi/enza
Publisert: 11.1.2021 -
Episode 73: The Uromigos meet APCCC in a discussion on oligometastatic prostate cancer @APCCC_Lugano
Publisert: 8.1.2021 -
Episode 72: Uromigos Christmas Special - Renal cancer year in review
Publisert: 21.12.2020 -
Episode 71: Bladder Cancer Uromigos Christmas Special with Matt Galsky
Publisert: 18.12.2020 -
Episode 70: The Uromigos Prostate Cancer Christmas Special with Chuck Ryan
Publisert: 11.12.2020 -
Episode 69: Testis Cancer Christmas Special: 2020 year in review
Publisert: 9.12.2020 -
Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell
Publisert: 8.12.2020 -
Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer
Publisert: 17.11.2020 -
Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer
Publisert: 9.11.2020 -
Episode 65: Review of the International Kidney Cancer Symposium
Publisert: 2.11.2020 -
Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC
Publisert: 28.10.2020 -
Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer
Publisert: 9.10.2020
Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
